Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | Pomoč | SLO | ENG

Naslov:Identification of plasma biomarker candidates in glioblastoma using an antibody-array-based proteomic approach
Avtorji:ID Zupančič, Klemen (Avtor)
ID Koršič, Marjan (Avtor)
ID Verbovšek, Urška (Avtor)
ID Rožman, Primož (Avtor)
ID Lah Turnšek, Tamara (Avtor)
ID Blejec, Andrej (Avtor)
ID Gruden, Kristina (Avtor)
ID Motaln, Helena (Avtor)
ID Knežević, Miomir (Avtor)
ID Veber, Matija (Avtor)
ID Herman, Ana (Avtor)
Datoteke:URL URL - Predstavitvena datoteka, za dostop obiščite http://www.degruyter.com/view/j/raon.2014.48.issue-3/raon-2014-0014/raon-2014-0014.xml?format=INT
 
.pdf PDF - Predstavitvena datoteka, prenos (621,07 KB)
MD5: D30E197A64963B5C4830441C4E10EECD
 
URL URL - Izvorni URL, za dostop obiščite https://doi.org/10.2478/raon-2014-0014
 
Jezik:Angleški jezik
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:Logo NIB - Nacionalni inštitut za biologijo
Povzetek:Background. Glioblastoma multiforme (GBM) is a brain tumour with a very high patient mortality rate, with a median survival of 47 weeks. This might be improved by the identification of novel diagnostic, prognostic and predictive therapy-response biomarkers, preferentially through the monitoring of the patient blood. The aim of this study was to define the impact of GBM in terms of alterations of the plasma protein levels in these patients. Materials and methods. We used a commercially available antibody array that includes 656 antibodies to analyse blood plasma samples from 17 healthy volunteers in comparison with 17 blood plasma samples from patients with GBM. Results. We identified 11 plasma proteins that are statistically most strongly associated with the presence of GBM. These proteins belong to three functional signalling pathways: T-cell signalling and immune responses; cell adhesion and migration; and cell-cycle control and apoptosis. Thus, we can consider this identified set of proteins as potential diagnostic biomarker candidates for GBM. In addition, a set of 16 plasma proteins were significantly associated with the overall survival of these patients with GBM. Guanine nucleotide binding protein alpha (GNAO1) was associated with both GBM presence and survival of patients with GBM. Conclusions. Antibody array analysis represents a useful tool for the screening of plasma samples for potential cancer biomarker candidates in small-scale exploratory experiments; however, clinical validation of these candidates requires their further evaluation in a larger study on an independent cohort of patients.
Ključne besede:glioblastoma, proteomics, biomarker
Status publikacije:Objavljeno
Verzija publikacije:Objavljena publikacija
Datum objave:04.12.2014
Leto izida:2014
Št. strani:str. 257-266, III
Številčenje:Vol. 48, no. 3
PID:20.500.12556/DiRROS-5185 Novo okno
ISSN:1318-2099
UDK:616.831-006-07
DOI:10.2478/raon-2014-0014 Novo okno
COBISS.SI-ID:31525081 Novo okno
Datum objave v DiRROS:02.08.2024
Število ogledov:7
Število prenosov:4
Metapodatki:XML RDF-CHPDL DC-XML DC-RDF
:
Kopiraj citat
  
Objavi na:Bookmark and Share


Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.

Gradivo je financirano iz projekta

Financer:Drugi - Drug financer ali več financerjev
Številka projekta:3211-06-000539
Naslov:Systems Biology Tools Development for Cell Therapy and Drug Development
Akronim:SYSTHER/ INREMOS project

Financer:ARIS - Javna agencija za znanstvenoraziskovalno in inovacijsko dejavnost Republike Slovenije
Številka projekta:P1-0245
Naslov:Ekotoksiologija, toksikološka genomika in karcinogeneza

Financer:ARIS - Javna agencija za znanstvenoraziskovalno in inovacijsko dejavnost Republike Slovenije
Številka projekta:MR09/27

Sekundarni jezik

Jezik:Slovenski jezik
Ključne besede:glioblastom, proteomika, biomarker


Nazaj